Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord-derived mesenchymal stem cells + bone marrow mononuclear cells
- Development stage
- Unknown
- Lead developer
- Translational Biosciences
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
This investigational cell therapy combination, developed by Translational Biosciences, consists of allogeneic human umbilical cord-derived mesenchymal stem cells (UC-MSC) and autologous bone marrow mononuclear cells (BMMC). It is currently being evaluated in Phase 1/2 clinical trials for the treatment of spinal cord injury (SCI). The therapeutic approach utilizes the synergistic effects of both cell types: UC-MSCs provide immunomodulatory and neurotrophic support to reduce secondary injury and promote a regenerative environment, while BMMCs, which include various progenitor populations, are intended to support revascularization and tissue repair. The treatment protocol involves a dual administration route, combining intravenous and intrathecal injections to optimize cell delivery to the central nervous system and systemic circulation.
- Other names
- UC-MSCBMMCUC-MSC + BMMCUC-MSC and BMMC
Beyond the preview
Go deeper on human umbilical cord-derived mesenchymal stem cells + bone marrow mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord-derived mesenchymal stem cells + bone marrow mononuclear cells.